Takeda Pharma of Japan has started enrolling patients in a Phase III trial conducted in China of alogliptin, an oral treatment for type 2 diabetes mellitus. Alogliptin is a dipeptidyl peptidase-IV (DPP-4) inhibitor. So far, the drug has been approved for use in Japan, where it was launched as Nesina. More details....

Stock Symbol: (TSE: 4502)